Sequence-dependent interaction of 5-fluorouracil and arabinosyl-5-azacytosine or 1-beta-D-arabinofuranosylcytosine

Biochem Pharmacol. 1991 Jul 5;42(2):409-18. doi: 10.1016/0006-2952(91)90729-o.

Abstract

We studied the cytotoxicity of arabinosyl-5-azacytosine (Ara-AC), a dCyd antagonist which inhibits DNA synthesis, in combination with 5-fluorouracil (FUra) in two human colon cancer cell lines, HCT 116 and SNU-C4. Clonogenic assays done following sequential or concurrent 24-hr exposures to Ara-AC and FUra showed that the sequence Ara-AC followed by FUra resulted in more than additive lethality in the HCT 116 cell lines and additive lethality in the SNU-C4 cells. In contrast, the reverse sequence, FUra followed by Ara-AC, was antagonistic in both cell lines. A similar interaction between FUra and 1-beta-D-arabinofuranosylcytosine (Ara-C) was evident in HCT 116 cells; at concentrations which individually diminished viability by 34 and 62%, respectively, the sequence Ara-C followed by FUra decreased viability by 97%. Pulse-labeling with [3H]dUrd showed profound inhibition of DNA synthesis by the sequence Ara-AC followed by FUra, with over 90% inhibition lasting for up to 48 hr following Ara-AC exposure. When FUra preceded Ara-AC, however, earlier recovery from inhibition of DNA synthesis occurred. FUra pretreatment did not appreciably alter the quantity or distribution of [3H]Ara-AC or [3H]Ara-C nucleotides after a 4- to 6-hr exposure. Pre-exposure to FUra decreased Ara-AC incorporation into DNA by 37 and 73% at 6 hr in HCT 116 and SNU-C4, respectively. FUra pretreatment also inhibited Ara-C incorporation into DNA by over 50% at 6 and 24 hr. The antagonism of Ara-AC and Ara-C cytotoxicity by FUra pretreatment can thus be explained by diminished incorporation of the dCyd analogs into DNA resulting from inhibition of DNA synthesis by FUra-induced dTTP and dCTP depletion. In contrast, when Ara-AC or Ara-C preceded FUra, their incorporation into DNA was not disturbed, and prolonged inhibition of DNA synthesis was observed.

MeSH terms

  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Azacitidine / administration & dosage
  • Azacitidine / pharmacology*
  • Cell Division / drug effects
  • Cell Line / drug effects
  • Cell Nucleus / drug effects
  • Cell Survival / drug effects
  • Colonic Neoplasms / drug therapy
  • Colonic Neoplasms / pathology*
  • Cytarabine / administration & dosage
  • Cytarabine / pharmacology*
  • Cytidine / antagonists & inhibitors
  • DNA, Neoplasm / biosynthesis
  • Deoxycytosine Nucleotides / metabolism
  • Drug Administration Schedule
  • Drug Interactions
  • Fluorouracil / administration & dosage
  • Fluorouracil / pharmacology*
  • Humans
  • Nucleic Acids / metabolism
  • Thymine Nucleotides / metabolism
  • Tumor Stem Cell Assay

Substances

  • DNA, Neoplasm
  • Deoxycytosine Nucleotides
  • Nucleic Acids
  • Thymine Nucleotides
  • Cytarabine
  • 2'-deoxycytidine 5'-triphosphate
  • Cytidine
  • fazarabine
  • Azacitidine
  • thymidine 5'-triphosphate
  • Fluorouracil